ABI2

Across TCGA pan-cancer cohorts, ABI2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ABI2 data layer compared with 26 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ABI2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ABI2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where ABI2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	All	0.959	0.705	.005	22	view →
LUAD	OS	Median	III,IV	0.308	1.000	.001	12	view →
PDAC	OS	Median	II,III,IV	0.708	0.944	.010	12	view →
GBM	OS	Tertile	All	0.948	0.675	.004	7	view →
HNSC	OS	Median	IV	0.643	0.835	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ABI2–CCRCC (OS)

Open the CCRCC breakdown →